Longitudinal assessment of antisaccades in patients with multiple sclerosis.

We have previously demonstrated that assessment of antisaccades (AS) provides not only measures of motor function in multiple sclerosis (MS), but measures of cognitive control processes in particular, attention and working memory. This study sought to demonstrate the potential for AS measures to sen...

Full description

Bibliographic Details
Main Authors: Joanne Fielding, Trevor Kilpatrick, Lynette Millist, Meaghan Clough, Owen White
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3271102?pdf=render
id doaj-5ec17910ed3344089c44f09e82f7794a
record_format Article
spelling doaj-5ec17910ed3344089c44f09e82f7794a2020-11-25T02:00:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0172e3047510.1371/journal.pone.0030475Longitudinal assessment of antisaccades in patients with multiple sclerosis.Joanne FieldingTrevor KilpatrickLynette MillistMeaghan CloughOwen WhiteWe have previously demonstrated that assessment of antisaccades (AS) provides not only measures of motor function in multiple sclerosis (MS), but measures of cognitive control processes in particular, attention and working memory. This study sought to demonstrate the potential for AS measures to sensitively reflect change in functional status in MS. Twenty-four patients with relapsing-remitting MS and 12 age-matched controls were evaluated longitudinally using an AS saccade task. Compared to control subjects, a number of saccade parameters changed significantly over a two year period for MS patients. These included saccade error rates, latencies, and accuracy measures. Further, for MS patients, correlations were retained between OM measures and scores on the PASAT, which is considered the reference task for the cognitive evaluation of MS patients. Notably, EDSS scores for these patients did not change significantly over this period. These results demonstrate that OM measures may reflect disease evolution in MS, in the absence of clinically evident changes as measured using conventional techniques. With replication, these markers could ultimately be developed into a cost-effective, non-invasive, and well tolerated assessment tool to assist in confirming progression early in the disease process, and in measuring and predicting response to therapy.http://europepmc.org/articles/PMC3271102?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Joanne Fielding
Trevor Kilpatrick
Lynette Millist
Meaghan Clough
Owen White
spellingShingle Joanne Fielding
Trevor Kilpatrick
Lynette Millist
Meaghan Clough
Owen White
Longitudinal assessment of antisaccades in patients with multiple sclerosis.
PLoS ONE
author_facet Joanne Fielding
Trevor Kilpatrick
Lynette Millist
Meaghan Clough
Owen White
author_sort Joanne Fielding
title Longitudinal assessment of antisaccades in patients with multiple sclerosis.
title_short Longitudinal assessment of antisaccades in patients with multiple sclerosis.
title_full Longitudinal assessment of antisaccades in patients with multiple sclerosis.
title_fullStr Longitudinal assessment of antisaccades in patients with multiple sclerosis.
title_full_unstemmed Longitudinal assessment of antisaccades in patients with multiple sclerosis.
title_sort longitudinal assessment of antisaccades in patients with multiple sclerosis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description We have previously demonstrated that assessment of antisaccades (AS) provides not only measures of motor function in multiple sclerosis (MS), but measures of cognitive control processes in particular, attention and working memory. This study sought to demonstrate the potential for AS measures to sensitively reflect change in functional status in MS. Twenty-four patients with relapsing-remitting MS and 12 age-matched controls were evaluated longitudinally using an AS saccade task. Compared to control subjects, a number of saccade parameters changed significantly over a two year period for MS patients. These included saccade error rates, latencies, and accuracy measures. Further, for MS patients, correlations were retained between OM measures and scores on the PASAT, which is considered the reference task for the cognitive evaluation of MS patients. Notably, EDSS scores for these patients did not change significantly over this period. These results demonstrate that OM measures may reflect disease evolution in MS, in the absence of clinically evident changes as measured using conventional techniques. With replication, these markers could ultimately be developed into a cost-effective, non-invasive, and well tolerated assessment tool to assist in confirming progression early in the disease process, and in measuring and predicting response to therapy.
url http://europepmc.org/articles/PMC3271102?pdf=render
work_keys_str_mv AT joannefielding longitudinalassessmentofantisaccadesinpatientswithmultiplesclerosis
AT trevorkilpatrick longitudinalassessmentofantisaccadesinpatientswithmultiplesclerosis
AT lynettemillist longitudinalassessmentofantisaccadesinpatientswithmultiplesclerosis
AT meaghanclough longitudinalassessmentofantisaccadesinpatientswithmultiplesclerosis
AT owenwhite longitudinalassessmentofantisaccadesinpatientswithmultiplesclerosis
_version_ 1724961630866898944